Clarivate
Subscription analytics for research and IP
Business Development Manager
Two to three days in the Tempe office per week are required; candidates must live within commuting distance.
About the job
- A bachelor's degree or equivalent experience is required.
- At least 5 years of business-to-business sales experience is required.
- At least 5 years of experience selling software, data, analytics, or services into life sciences or pharmaceutical organizations is required.
- Own the end-to-end sales process from prospecting and discovery through proposal, negotiation, and close.
- Generate new business through outbound prospecting, inbound lead conversion, and strategic account targeting.
- Engage senior decision makers to uncover business challenges, priorities, and buying drivers.
- Position Clarivate solutions as strategic investments supporting research and development, commercial, and corporate decision making.
- Build, manage, and forecast a healthy pipeline aligned to quarterly and annual revenue targets.
- Collaborate with Business Development Associates, Solution Consultants, and cross-functional partners to advance opportunities efficiently.
- Attend and support industry conferences and events to drive new logo pipeline and deepen customer relationships.
- Maintain accurate activity and opportunity tracking in Salesforce.
- Continuously develop expertise across Clarivate's product portfolio and relevant industry trends.
- A degree in pharmaceutical, biotechnology, life sciences, or medical sciences is preferred.
- Demonstrated experience managing opportunities through the full sales cycle is preferred.
- Familiarity with United States pharmaceutical, biotechnology, or healthcare markets is preferred.
- Proven ability to present to Director, Vice President, and C-level stakeholders is preferred.
- Experience generating new business through outbound prospecting is preferred.
- Experience attending and leveraging industry conferences for pipeline generation is preferred.
- Proficiency with Salesforce or a similar customer relationship management system is preferred.
About the company
Clarivate provides subscription-based analytics platforms and services focused on bibliometrics, scientometrics, business and patent intelligence, and regulatory standards for researchers, organizations, and regulators. Its products, including Web of Science and Derwent World Patents Index, give access to citation and patent data through a subscription model, enabling users to search, analyze, and generate reports. It stands out by offering an integrated suite that spans academia, intellectual property, and regulatory domains, backed by long-standing, curated data and trusted brands. The goal is to help organizations accelerate innovation and protect and manage their intellectual assets through reliable data, analytics, and regulatory intelligence.
Company Size
10,001+
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
2016
Get referred to Clarivate
See people who can refer or advise you
Simplify's Take
What believers are saying
- The July 2026 Altaris sale of Life Sciences & Healthcare lifts recurring mix toward 92%.
- Q2 2026 adjusted EPS hit $0.19, beating estimates while free cash flow stayed positive.
- Clarivate bought back $75 million of 2028 bonds and cut first-half debt $218 million.
What critics are saying
- Q2 2026 revenue fell 5.5%, and organic revenue declined 1.5% despite AI launches.
- The $221.7 million goodwill impairment proves the Life Sciences exit destroyed reported earnings.
- Eastern District of New York securities litigation remains open through discovery, extending management distraction.
What makes Clarivate unique
- May 6, 2026, Web of Science Research Intelligence paired curated data with academic AI.
- Clarivate Nexus launched January 22, 2026, embedding library content inside students' existing AI tools.
- IPOne and Cortellis agentic AI automate patent, trademark, and drug-development workflows for subscribers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Flexible Work Hours
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 35%1 year growth
↑ 35%2 year growth
↑ 40%- Creates end-to-end solution covering the entire intellectual property, science and innovation lifecycle - Clarivate reaffirms standalone 2020 financial outlook Clarivate Plc (NYSE: CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today the completion of the previously announced acquisition of CPA Global, creating an intellectual property ("IP") powerhouse. "This is an exciting day for our company as we unite with CPA Global to offer our combined global customer base a more comprehensive suite of IP related products and services," said Jerre Stead, Executive Chairman and CEO of Clarivate. "With our joint resources and exceptional people, we are well positioned to accelerate the ways in which organizations can more effectively identify new opportunities, avoid risks, and act more efficiently throughout the innovation lifecycle." Simon Webster, formerly CEO of CPA Global and now Executive Advisor to the CEO at
AI-Driven SaaS earnings power Tech stock upswing. SaasRise - Aug 17, 2026 AI-centric SaaS companies such as Doximity and Clarivate reported robust earnings and raised guidance, helping lift software stocks this month. The earnings beat highlights growing demand for AI-enhanced workflow tools and data-intelligence platforms. Why it matters. The strong earnings from AI-centric SaaS firms illustrate a shift in the software market: AI is no longer a peripheral add-on but a core growth engine. High net-revenue retention and accelerated bookings indicate that customers are willing to pay premium prices for AI-enhanced productivity, creating defensible revenue streams and higher expansion rates. For investors, these results validate higher multiples for AI-native SaaS companies, while for operators they highlight the strategic imperative to embed AI deeply into product and GTM strategies. Moreover, the rebound in software equities suggests that the market is re-pricing risk around AI adoption. Companies that can demonstrate measurable AI-driven ROI are likely to capture a larger share of the growing enterprise spend on automation and data intelligence, reinforcing competitive moats and fueling further valuation upside. Key points. * Doximity Q1 revenue $156.6M (+7% YoY) and raised FY2027 guidance to $671-$681M * Clarivate Q2 revenue $257.5M (+6.6% YoY) with bookings $30M ACV, 150% YoY growth * Both firms reported net-revenue retention above 100%, indicating strong expansion revenue * AI-driven product launches (Doximity AI search, Clarivate claims-intelligence) are central to growth * Tech market sentiment turned positive, with Nasdaq 100 futures up 0.2% and S&P 500 hitting fresh highs Analysis. The earnings surge from Doximity and Clarivate marks a inflection point for AI-enabled SaaS. Historically, AI has been a differentiator for a subset of high-growth software firms, but the current wave shows it becoming a baseline expectation for enterprise productivity tools. This shift mirrors the early 2010s transition when cloud infrastructure moved from a cost-center to a strategic asset; today, AI is the new strategic layer that drives both top-line expansion and pricing power. From a competitive dynamics perspective, firms that have built AI into the core of their platforms - rather than bolting it on - are achieving higher gross margins and NRR, as seen with Doximity's 87.5% non-GAAP gross margin and Clarivate's 60.5% adjusted EBITDA margin. This suggests that AI-native architectures enable more efficient scaling of compute resources and better data capture, which in turn fuels cross-sell and upsell opportunities. Companies still relying on legacy SaaS models without AI integration may find themselves pressured on pricing and churn. Looking forward, the market will likely reward firms that can demonstrate concrete AI ROI, such as reduced time-to-insight or measurable cost savings for customers. As AI compute costs normalize, the margin upside could be significant, especially for platforms that can monetize AI as a separate subscription tier. Investors should watch for guidance on AI-specific ARR and the pace of AI-driven expansion revenue, while operators must prioritize data hygiene, model governance, and seamless UX to sustain the current momentum.
Clarivate opens up library metadata with enhanced SkyRiver. 12 August 2026 Clarivate has launched an enhanced version of its SkyRiver platform, with a focus on open bibliographic metadata, interoperability and AI-assisted record creation for libraries. The company said the updated platform is designed to give libraries a more affordable way to source, manage and share bibliographic metadata across institutions, consortia and different library management systems. SkyRiver uses open metadata by default, with records intended to be as reusable as possible while still respecting contributor requirements, licensing obligations and institutional governance policies. Libraries retain control over whether and how they participate and contribute metadata. The launch comes as libraries face growing pressure to improve efficiency while adapting their discovery services. Clarivate argues that trusted and interoperable metadata will become increasingly important to those services, particularly as artificial intelligence plays a greater role in discovery and cataloguing. The enhanced SkyRiver platform includes AI-powered record creation capabilities intended to make the creation of high-quality metadata more efficient. Yoel Goldenberg, Senior Vice President, Product Management, Academia & Government at Clarivate, said: "Libraries need trusted metadata that can be shared, reused and integrated across systems without sacrificing choice, transparency or governance. "The enhanced SkyRiver platform helps libraries work more efficiently through community open metadata sharing, while introducing AI-powered capabilities that make it easier to create high-quality records. As libraries explore the future of discovery, trusted metadata will be more important than ever." Clarivate said the platform is intended to enable libraries to exchange and reuse metadata across different library management systems and improve interoperability between individual institutions, consortia and wider library networks. Users will also have access to information about the rights, sources, attribution and access conditions associated with metadata. The approach is intended to allow institutions to reuse open bibliographic metadata while retaining local control and respecting contributor and licensing requirements. Trevor A. Dawes, Vice Provost for Libraries and Museums and May Morris University Librarian, University of Delaware, said: "Our partnership with Clarivate on SkyRiver reflects our commitment to high-quality, open metadata that increases the visibility and discoverability of our collections while supporting collaboration across the library community." Brett Waytuck, Dean, University Libraries and Archives, University of Regina, said: "Discoverability depends on trusted metadata and workflows that recognise the value libraries contribute. The enhanced SkyRiver platform presents an opportunity to explore a practical approach that preserves local metadata enhancements, integrates with existing operations and helps libraries realise greater value from their collections." Alongside the platform launch, Clarivate plans to establish a Metadata Governance Advisory Group. The group will provide community input into the future development of SkyRiver, including its metadata policies, quality standards and governance principles. Clarivate said the initiative forms part of a wider commitment to transparency and community engagement around the development and use of bibliographic metadata.
Clarivate has expanded agentic AI capabilities across its Cortellis portfolio to help life sciences organisations accelerate drug development. The enhanced platform integrates AI into existing workflows, enabling research and development teams to reduce manual work and make faster decisions throughout the drug development lifecycle. The Cortellis suite combines life sciences data, expert curation, and AI to support R&D, portfolio strategy, business development, and regulatory professionals. The latest AI features aim to speed up work across discovery, safety assessment, and portfolio strategy. Anne Lecocq, senior vice president and general manager for R&D at Clarivate, said the platform has evolved from delivering insights to executing workflows across the product lifecycle. The system is built on proprietary data and embedded AI to help teams connect evidence and streamline complex processes.
Clarivate reported Q2 revenue of $587.3 million, down 5.5% year-over-year, slightly beating the consensus estimate of $587.06 million. The company posted earnings per share of $0.19, up from $0.18 a year ago and surpassing analyst expectations of $0.17. By segment, Life Sciences & Healthcare revenue fell 11.7% to $88.7 million, missing estimates of $93.25 million. Academia & Government revenue declined 5.7% to $300.3 million, exceeding the $294.8 million estimate. Intellectual Property revenue dropped 2.1% to $198.3 million, above the projected $197.2 million. Clarivate shares have risen 11.1% over the past month, outperforming the S&P 500's 1.9% gain. The stock currently holds a Zacks Rank 3 rating.